Overview

Starving a tumor of its blood supply remains one of the most broadly applicable targeted strategies in solid oncology. Lenvatinib (Lenvima) 4 mg capsules are a multi-target tyrosine-kinase inhibitor whose anti-angiogenic action underpins use across thyroid, renal, and liver cancers. For B2B buyers the addressable population spans several distinct indications, each with its own dosing convention. We help distributors match the correct strength and pack size to the intended clinical setting. Coordinated supply planning prevents stockouts across these parallel demand streams.

How It Works

Lenvatinib blocks the vascular endothelial growth factor receptors VEGFR1, VEGFR2, and VEGFR3, cutting off the angiogenic signaling tumors use to build feeding vessels. It also inhibits FGFR, PDGFR, RET, and KIT, giving it a broader kinase footprint than single-target agents. The practical result is reduced tumor perfusion and slowed growth across multiple tumor types. From a procurement view the implication is versatility: one molecule serves several indication-specific regimens. Distributors should align inventory with the dominant indication in their market.

Indications

The 4 mg capsule is indicated in differentiated thyroid cancer, in renal-cell carcinoma in combination with an immunotherapy partner, and in hepatocellular carcinoma as single-agent or combination therapy, per the local label. Eligibility and partner agents differ by indication, so importers must confirm the licensed use in each market. We supply the listed 30-capsule pack to match the once-daily capsule regimen.

Dosage & Administration

Lenvatinib is taken as a once-daily capsule, with the dose varying by indication: higher weight-based doses in thyroid cancer and lower, combination-aligned doses in renal and liver settings. Capsules should be swallowed whole and stored in the original container with desiccant. Because dosing is indication-specific, procurement should confirm the intended regimen before ordering. We advise forecasting from the treated population of each licensed indication separately.

Storage & Sourcing

Store the capsules at 2-8°C and protect them from light and moisture. Our export packaging uses validated cold-chain materials with transit temperature logging. Minimum order quantities and lead times are confirmed per contract, with priority given to continuity across parallel indications. Each delivery includes batch-release documentation appropriate for pharmacy and customs acceptance.

FAQ

Q: How does Lenvatinib block tumor blood supply? It inhibits VEGFR1-3, shutting down the VEGF-driven angiogenesis that tumors rely on to build feeding vessels.

Q: Why is the dose different across indications? Thyroid cancer uses higher weight-based dosing, while renal and liver settings use lower, combination-aligned doses per the label.

Q: What monitoring should distributors highlight? Blood-pressure control is central, since anti-angiogenic therapy commonly raises hypertension.

Q: Is the product used alone or in combination? It is used both as monotherapy and with a partner agent depending on the licensed indication.